Panorama of adverse events during cytapheresis

Stegmayr, Bernd; Pták, Jan; Nilsson, Thomas; Berlin, Gösta; Mirea,; Axelsson, CG; Griskevicius, A.; Centoni, Paolo Emilio; Liumbruno, Giancarlo Maria; Audzijoniene, J.; Mokvist, K; Lassen, Ewa; Knutson, Folke; Norda, Rut; Mörtzell, Monica; Prophet, Heinrich; Ramlow, Wolfgang; Bláha, M.; Witt,; M, Efvergren; Tomaz, J.; Newman, Elizabeth; Eloot, Sunny; Dhondt, Annemieke; Lalić, K.; Šikole, Aleksandar; Derfler, Kurt; Hrdličková, Radomíra; Tomsova, H.; Gašová, Z; Bhuiyan-Ludvikova, Z.; Ramsauer, Bernd; Vrielink, H.

doi:10.1016/j.transci.2013.02.014

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Jako pracoviště registrované ve světovém registru hemaferéz WAA -Word Apheresis Registry jsme tuto metodu hlásili do centra a byla přijata a doporučena k provádění. Kladné výsledky s touto prevencí byly publikovány společně v letech 2009 a 2010 [37,38].…”

Section: Nežádoucí účInky Rheoferézyunclassified

Rheopheresis in the Treatment of Age-Related Macular Degeneration

Langrová¹,

Rencová²,

Bláha³

et al. 2023

CSO

View full text Add to dashboard Cite

Purpose: Evaluation of the long-term effect of rheopheresis treatment of dry form of age-related macular degeneration (AMD). Materials and Methods: The treatment group consisted of 65 patients and 55 patients in the control group, with a minimum follow-up period of 60 months. The basic treatment consisted of 8 rheopheresis procedures, and the additional treatment (booster therapy) of 2 rheopheresis procedures 1.5–2 years after the basic treatment. We evaluated changes in best corrected visual acuity, anatomical effect, electrical activity of the retina, haematological, biochemical and immunological parameters. Results: Rheopheresis treatment contributed significantly: 1) to stabilisation of best corrected visual acuity of the treated patients, which initially showed an insignificant increased during the 2-years follow-up period, and then slightly decreased. By contrast, visual acuity decreased in the control group, to an insignificant degree up to 4 years, then statistically significantly. 2) to an improvement of the morphological findings in 62.4% of treated patients compared to 7.5% in the control group, while disease progression to stage 3 (neovascular form of the disease or geographic atrophy) with a significant decrease of visual acuity occurred in only 7.1% of treated patients, versus 37.0% in the control group. 3) to regression, even to the attachment of drusenoid pigment epithelial detachment (DPED). To a reduction of the area of DPED in 80.4% of treated patients, in contrast with an increase in the area of DPED in 47.1% of patients in the control group, and the development of new DPED in only 2 eyes of treated patients compared with 16 eyes of patients in the control group. 4) to a preservation of the integrity of the ellipsoid layer in the fovea in 68.2% of the treated patients, while by contrast we found a damaged ellipsoid layer in the fovea in 66.6% of the control patients. 5) to a stabilisation of the activity of ganglion cells, the pineal system and the activity of the central area of the retina, with eccentricity between 1.8° and 30° in the treated patients, compared to alteration in the control group manifested mainly after 3.5 years of the follow-up period. 6) to a statistically significant improvement in rheological parameters, thereby increasing flow in microcirculation and positively influencing the metabolism in the retina. Also to a positive effect on the classical, alternative and lectin pathway of complement activation, a reduction in the level of proprotein convertase subtilisin kexin 9 (PCSK9), and thus also the level of LDL-cholesterol, and 7) Additional treatment with 2 RHF procedures (so-called "booster therapy") seems to be a safe and suitable method of prolonging the stabilisation phase, or even improving visual acuity, anatomical and functional findings. Conclusion: We demonstrated positive changes in anatomical, functional and humoral parameters upon rheopheresis treatment of AMD. Their correlation provides a real possibility to identify patients at risk and to manage an individualised regime of rheopheresis therapy. This method of treatment is effective and safe, with a low percentage of non-serious adverse effects.

show abstract

Section: Nežádoucí účInky Rheoferézyunclassified

Rheopheresis in the Treatment of Age-Related Macular Degeneration

Langrová¹,

Rencová²,

Bláha³

et al. 2023

CSO

View full text Add to dashboard Cite

show abstract

“…The progressive participation of centers and countries has improved the extent of available data and thereby increased statistical power. Registry reports have included data that help understand effects and side effects in the process of collecting blood and plasma for autologous or allogeneic measures [4, 5, 11-17]. This paper deals with the distribution of some diagnoses and reports recent data of side effects included in the WAA registry.…”

Section: Introductionmentioning

confidence: 99%

Using the World Apheresis Association Registry Helps to Improve the Treatment Quality of Therapeutic Apheresis

Stegmayr

Newman²,

Witt

et al. 2021

Transfus Med Hemother

View full text Add to dashboard Cite

Therapeutic apheresis (TA) is prescribed to patients that suffer from a severe progressive disease that is not sufficiently treated by conventional medications. A way to gain more knowledge about this treatment is usually by the local analysis of data. However, the use of large quality assessment registries enables analyses of even rare findings. Here, we report some of the recent data from the World Apheresis Association (WAA) registry. Data from >104,000 procedures were documented, and TA was performed on >15,000 patients. The main indication for TA was the collection of autologous stem cells (45% of patients) as part of therapy for therapy. Collection of stem cells from donors for allogeneic transplantation was performed in 11% of patients. Patients with indications such as neurological diseases underwent plasma exchange (28%). Extracorporeal photochemotherapy, lipid apheresis, and antibody removal were other indications. Side effects recorded in the registry have decreased significantly over the years, with approximately only 10/10,000 procedures being interrupted for medical reasons. <b><i>Conclusion:</i></b> Collection of data from TA procedures within a multinational and multicenter concept facilitates the improvement of treatment by enabling the analysis of and feedback on indications, procedures, effects, and side effects.

show abstract